.New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p < .001). Results from the Read more…
New data suggest
that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the
onset of a new episode of depression in patients who had previously
responded to the medication and who had recurrent depressive
disorder, defined in the study as those patients who experienced at
least three depressive episodes in the previous five years, compared
with placebo (p < .001).? Results Read more…
People suffering from anxiety and depression prefer to receive counselling over medication because they feel it addresses their underlying problems and not just their symptoms.
This is one of the key findings in a review of UK and international research studies into the clinical-effectiveness, cost-effectiveness and acceptability of counselling. The review, Counselling Read more…
Heart patients should be
screened for depression — a common condition that can profoundly affect
both prognosis and quality of life — according to the American Heart
Association’s first scientific statement on depression and coronary heart
disease. The statement was published in Circulation: Journal of the
American Heart Association.
The recommendations, which are endorsed by the American Psychiatric
Association, Read more…
In a large group of Medicare beneficiaries with diabetes, depression was associated with a higher death rate from all causes during a two-year study period. The findings are published in the October 2008 Journal of General Internal Medicine.
Lead author Dr. Wayne Katon, professor of psychiatry and behavioral sciences at the University of Washington (UW), noted Read more…
Valdoxan® today received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with Major Depressive Episodes (MDE).1
Valdoxan is an innovative approach to the treatment of MDE and has demonstrated convincing efficacy in depressed patients with Read more…
Suicide rates in those aged 10-19 in the UK declined by 28% in the seven year period from 1997-2003, shows a study published today in The Journal of Child Psychology and Psychiatry. The study, carried out by researchers at the University of Manchester, showed that the decline was particularly marked in young males, where rates declined by 35%.
Despite the decline, however, suicide remains Read more…
Women who took the antidepressant fluoxetine during the first three months of
pregnancy gave birth to four times as many babies with heart problems as women
who did not and the levels were three times higher in women taking paroxetine.
Although some of the conditions were serious, others were not severe and resolved
themselves without the need for medical Read more…
Although complete nonresponse in depression treatment is considered to be a major problem in clinical practice, research in this area is Read more…
The law firm of Izard Nobel LLP, which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the Southern District of New York Read more…
GPs prescribe lower volumes of antidepressants in areas with more Black or South Asian people, suggesting possible disparities in the provision of care.
The study, published in the September issue of the British Journal of Psychiatry, also reveals that higher volumes of antidepressants are prescribed by general practices in economically deprived areas, and by practices Read more…
The American College of Physicians is publishing a new guideline for the treatment of depression in Annals of Internal Medicine. ACP found no substantial differences in efficacy or quality of life among "second-generation" antidepressants used to treat Read more…
Two studies presented today at the 8th International Forum on Mood and Anxiety Disorders (IFMAD) in Vienna demonstrated that once-daily SEROQUEL XRTM (quetiapine fumarate extended release tablets) provided significant symptom relief for elderly patients (>65 years of age) with major depressive disorder Read more…
CeNeRx BioPharma,
Inc., a clinical stage company developing and commercializing innovative
treatments for diseases of the central nervous system, announced that
it has initiated a Phase II clinical trial for its lead product candidate
Tyrima(TM) Read more…
The treatment of pancreatic cancer remains a great challenge. The majority of patients with pancreatic cancer developed major depression. Antidepressant treatment has been accepted as one of the new strategies in cancer adjuvant therapy. However, systemic studies on the treatment of depression in patients with cancer have not been well documented.
A research article published in Read more…
Transcranial Magnetic Stimulation (TMS) therapy has received clearance from the U.S. Food and Drug Administration (FDA) and is now an entirely new treatment option for patients suffering from depression.
Generic viagra pills no prescription Dr. Phil Janicak, a professor of psychiatry at Rush University Medical Center, was the principal investigator for Read more…
People taking prescription antidepressants appear to drive worse than people who aren’t taking such drugs, and depressed people on antidepressants have even more trouble concentrating and reacting behind the wheel.
These were the conclusions of a study released Sunday at the Annual Convention of the American Psychological Association.
University of North Read more…
Prescriptions filled for antidepressant drugs increased from 154 million in 2002 to 170 million in 2005, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Among the prescriptions (not including refills) which were written after patients talked with doctors in-person or over the phone. AHRQ Read more…
New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month Read more…
Patients suffering from major depression are at an increased risk for cardiovascular disease, but treating these patients with medication can greatly reduce the risk, according to new findings by researchers at the University of Miami Miller School of Medicine. The results of their study Read more…
Decision Resources, one of the
world’s leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that a drug’s long-term efficacy in preventing
recurrence of depressive mood episodes in patients who suffer from major
depressive disorder, is the attribute that most influences psychiatrists’
prescribing decisions in the treatment of this disorder. Read more…
A new Mayo Clinic study shows that variations in the serotonin transporter gene could explain why some people with depression respond better than others to treatment with citalopram (Celexa), an antidepressant medication.
The study, in the current issue of the American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, examined the serotonin transporter gene, or SLC6A4, in 1,914 Read more…
Scientific evidence has long suggested that moderate drinking offers some protection against heart disease, certain types of stroke and some forms of cancer.
But new research shows that stopping drinking - including at moderate levels - may lead to health problems including depression and a reduced capacity of the brain to produce new neurons, a process called neurogenesis.
The findings from Read more…
A single antidepressant tablet makes a depressed person see the world in a more positive light just four hours after swallowing it, a new study has shown.
Dr Philip Cowen, professor of pharmacology at the Department of Psychiatry at the Read more…
An article published in The Lancet finds that
cancer patients who received a care package called "Depression Care for
People with Cancer" (DCPC) had lower levels of depression than those
who received the usual care (antidepressants and mental health services
recommended by the cancer team). Professor Michael Sharpe (University
of Edinburgh, UK) and other Read more…